Clinical trials: Urinary Bladder Overactive
Overactive Bladder
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment…
- Trial name
- NCT04103450
- Testing
- Vibegron
- Where
- 35 sites in United States, Poland
- Volunteers
- 276 people
- Sponsor
- Urovant Sciences GmbH
Neurogenic Overactive Bladder, Urinary Incontinence
Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder
The study is designed to demonstrate that treatment with low level stimulation of the bladder muscles reduces symptoms of urinary incontinence in comparison with no stimulation.
- Conditions
- Neurogenic Overactive Bladder, Urinary Incontinence, Detrusor Overactivity
- Trial name
- ACCEPTANCE (NCT01023269)
- Testing
- InterStim Therapy
- Where
- 8 sites in Belgium, France and 4 more
- Volunteers
- 17 people
- Sponsor
- MedtronicNeuro
Overactive Bladder Syndrome
Study of V117957 in Overactive Bladder Syndrome
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with overactive bladder syndrome, compared to placebo.
- Trial name
- NCT06024642
- Testing
- V117957
- Where
- 12 sites in United States
- Volunteers
- 51 people
- Sponsor
- Imbrium Therapeutics
Overactive Bladder
The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides
The medical field is beginning to adopt treatments that alter an individual's microbiome to improve patient health; however, this approach has not been adopted for treatment of lower urinary tract symptoms (LUTS).
- Trial name
- NCT02524769
- Testing
- conjugated estrogen
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Loyola University
Urinary Bladder, Overactive
An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants
The objective of this study is to evaluate the efficacy of oxybutynin chloride oral osmotic therapeutic system (OROS) on patient-reported outcomes after 12 weeks of treatment by dose escalation in participants with overactive…
- Trial name
- NCT00613327
- Testing
- Oxybutynin chloride OROS
- Volunteers
- 345 people
- Sponsor
- Janssen Korea, Ltd., Korea
Overactive Bladder
Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB)
The purpose of this study is to determine whether the non-invasive neurostimulation patch is effective in the treatment of urgency, frequency and urge (urinary) incontinence.
- Trial name
- NCT01125722
- Testing
- Non-invasive neurostimulation device
- Where
- 11 sites in United States, Sweden and 1 more
- Volunteers
- 74 people
- Sponsor
- Ethicon Endo-Surgery
Urinary Retention, Urinary Urge Incontinence
Axonics SacRal NeuromodulaTIon System RegisTRY Study
To assess the post-market clinical outcomes with use of the Axonics Sacral Neuromodulation System(s).
- Conditions
- Urinary Retention, Urinary Urge Incontinence, Urgency-Frequency, Fecal Incontinence
- Trial name
- ARTISTRY (NCT05064384)
- Where
- 27 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- Axonics, Inc.
Urinary Bladder, Overactive
A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.
Patients with overactive bladder are often treated with tolterodine, a medication that helps relax the bladder, helping symptoms of urinary incontinence and urinary frequency.
- Trial name
- NCT01302054
- Testing
- Fesoterodine 8 mg
- Where
- 176 sites in United States, Bulgaria and 13 more
- Volunteers
- 990 people
- Sponsor
- Pfizer
Overactive Bladder
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.
- Trial name
- NCT03902080
- Testing
- Vibegron
- Where
- 140 sites in United States, Belgium and 6 more
- Volunteers
- 1,105 people
- Sponsor
- Urovant Sciences GmbH
Urinary Bladder, Overactive
A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076
This was a 40-week study to investigate how safe and effective solifenacin solution was in treating children or adolescents with symptoms of overactive bladder (OAB), who completed study 905-CL-076 (NCT01565707).
- Trial name
- LEOPARD (NCT01655069)
- Testing
- Solifenacin succinate suspension
- Where
- 39 sites in United States, Belgium and 14 more
- Volunteers
- 148 people
- Sponsor
- Astellas Pharma Europe B.V.
Urinary Bladder, Overactive, Urinary Incontinence
Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence
This study will evaluate the efficacy and safety of onabotulinumtoxinA 100 U (BOTOX®), compared to placebo, when injected into the bladder using an alternative injection paradigm in reducing the number of daily urinary…
- Trial name
- LO-BOT (NCT03052764)
- Testing
- onabotulinumtoxinA
- Where
- 31 sites in United States
- Volunteers
- 120 people
- Sponsor
- Allergan
Overactive Bladder
A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)
This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in patients with OAB.
- Trial name
- Empowur (NCT03492281)
- Testing
- vibegron, Tolterodine Tartrate ER
- Where
- 215 sites in United States, Canada and 4 more
- Volunteers
- 1,530 people
- Sponsor
- Urovant Sciences GmbH
Overactive Bladder Syndrome, Urinary Incontinence, Urge
Effectiveness of Bilateral PTNS Compared to Unilateral PTNS for the Treatment of Overactive Bladder/Urge Incontinence
This study is designed to evaluate whether bilateral Posterior Tibial Nerve Stimulation is more effective than unilateral Posterior Tibial Nerve Stimulation at treating overactive bladder and urge urinary incontinence
- Trial name
- BUTTON (NCT03535857)
- Testing
- PTNS
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Gnankang Sarah Napoe
Overactive Bladder
Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms
The purpose of this study is to determine if long acting tolterodine confers more benefit than intravaginal low dose estrogen in the treatment of Overactive Bladder Syndrome at 12 weeks post-treatment initiation.
- Trial name
- DRIVE (NCT00465894)
- Testing
- Extended Release Tolterodine LA, Intra Vaginal Estradiol Cream
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Pelvic Organ Prolapse, Stress Urinary Incontinence
Impact of Decision Aids in Urogynecology
To evaluate how patient knowledge and confidence in decision making can be impacted by shared decision making in common urogynecology conditions.
- Conditions
- Pelvic Organ Prolapse, Stress Urinary Incontinence, Overactive Bladder
- Trial name
- NCT04369404
- Testing
- Pelvic organ prolapse decision aid, Stress urinary incontinence decision aid, Overactive bladder decision aid
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Massachusetts General Hospital
Overactive Bladder
A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis
The purpose of this study is to assess the long-term safety and effectiveness of botulinum toxin type A on patients with overactive bladder as a result of spinal cord injury or multiple sclerosis.
- Trial name
- NCT00876447
- Testing
- Botulinum Toxin Type A 300U, Botulinum Toxin Type A 200U
- Where
- 22 sites in United States, Australia and 20 more
- Volunteers
- 397 people
- Sponsor
- Allergan
Overactive Bladder, Overactive Detrusor
Minimizing Pain During Office Intradetrussor Botox Injection
This will be a prospective double-blinded randomized controlled trial comparing two pre-treatment protocols for patients undergoing intradetrussor botox injections to determine if a buffered lidocaine solution offers superior…
- Conditions
- Overactive Bladder, Overactive Detrusor, Overactive Bladder Syndrome, Overactivity; Behavior
- Trial name
- NCT04270526
- Testing
- Bicarbonate protocol, Standard protocol
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Boston Urogynecology Associates
Urologic Diseases, Urodynamics
Modern Urodynamics System Efficacy (MUSE) Study
The goal of this prospective trial is to evaluate the feasibility, efficacy, and safety of the Glean Urodynamics System (GUS) for use in the clinic to collect vesical pressure data in adult males and females with lower urinary…
- Trial name
- MUSE (NCT05959655)
- Testing
- Glean Urodynamics System
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- Bright Uro
Urinary Bladder, Overactive
UK Study Assessing Flexible Dose Fesoterodine in Adults
To explore the effects of fesoterodine when used in a flexible dose manner
- Trial name
- SAFINA (NCT00806494)
- Testing
- Fesoterodine
- Where
- 39 sites in United Kingdom
- Volunteers
- 331 people
- Sponsor
- Pfizer
Overactive Bladder
Sham Controlled Trial of Rapid Induction Percutaneous Tibial Nerve Stimulation
The aim of this study is to determine the efficacy of an accelerated course for percutaneous tibial nerve stimulation (PTNS) induction to treat overactive bladder symptoms.
- Trial name
- NCT03547518
- Testing
- PTNS treatment
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Corewell Health East